Last mentioned: Mar 24, 2026
Regulatory Submission
Target window for potential FDA submission for DeepView System clearance.
Data Collection Completion
Expected completion of clinical data collection for burn applications.
Clinical Study Expansion
Commencement of expanded clinical validation studies for burn care.
Q4 Earnings Release
Spectral AI reports Q4 revenue beat and introduces 2026 revenue guidance.
BARDA Award
Company receives $31.7 million in non-dilutive funding for the DeepView System.
BARDA Award Announced
Spectral AI receives $31.7M in additional funding for DeepView development.
Fiscal Year End
Spectral AI closes FY2025 with $19.7M in R&D revenue and $15.4M in cash.
Spectral AI reported a significant Q4 2025 earnings beat with revenue of $3.8 million and a surprise GAAP profit, bolstered by a recent $31.7 million BARDA award. The company has introduced its first revenue guidance for 2026, marking a critical transition from R&D to commercial-scale medical AI diagnostics.
Spectral AI has been awarded $31.7 million in additional funding from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development and clinical validation of its DeepView® System. This non-dilutive capital will support the company's efforts to bring AI-driven diagnostic precision to burn and wound care, particularly for mass casualty scenarios.
This page surfaces every story mentioning BARDA across our ai coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running ai beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where BARDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |